Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 195

1.

Association Between Endoscopic and Histologic Findings in a Multicenter Retrospective Cohort of Patients with Non-esophageal Eosinophilic Gastrointestinal Disorders.

Pesek RD, Reed CC, Collins MH, Muir AB, Fulkerson PC, Menard-Katcher C, Falk GW, Kuhl J, Magier AZ, Ahmed FN, Demarshall M, Gupta A, Gross J, Ashorobi T, Carpenter CL, Krischer JP, Gonsalves N, Hirano I, Spergel JM, Gupta SK, Furuta GT, Rothenberg ME, Dellon ES; Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR).

Dig Dis Sci. 2019 Nov 26. doi: 10.1007/s10620-019-05961-4. [Epub ahead of print]

PMID:
31773359
2.

Molecular, Endoscopic, Histologic and Circulating Biomarker-Based Diagnosis of Eosinophilic Gastritis: Multi-Site Study.

Shoda T, Wen T, Caldwell JM, Collins MH, Besse JA, Osswald GA, Abonia JP, Arva NC, Atkins D, Capocelli KE, Dellon ES, Falk GW, Gonsalves N, Gupta SK, Hirano I, Mukkada VA, Putnam PE, Sheridan RM, Spergel Ak R, Spergel JM, Wechsler JB, Yang GY, Aceves SS, Furuta GT, Rothenberg ME; Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR).

J Allergy Clin Immunol. 2019 Nov 15. pii: S0091-6749(19)31519-2. doi: 10.1016/j.jaci.2019.11.007. [Epub ahead of print]

PMID:
31738990
3.

Emerging therapies for eosinophilic esophagitis.

Greuter T, Hirano I, Dellon ES.

J Allergy Clin Immunol. 2019 Nov 6. pii: S0091-6749(19)31474-5. doi: 10.1016/j.jaci.2019.10.027. [Epub ahead of print]

PMID:
31705907
4.

Efficacy of Dupilumab in a Phase 2 Randomized Trial of Adults With Active Eosinophilic Esophagitis.

Hirano I, Dellon ES, Hamilton JD, Collins MH, Peterson K, Chehade M, Schoepfer AM, Safroneeva E, Rothenberg ME, Falk GW, Assouline-Dayan Y, Zhao Q, Chen Z, Swanson BN, Pirozzi G, Mannent L, Graham NMH, Akinlade B, Stahl N, Yancopoulos GD, Radin A.

Gastroenterology. 2019 Oct 5. pii: S0016-5085(19)41415-7. doi: 10.1053/j.gastro.2019.09.042. [Epub ahead of print]

5.

One-Hour Esophageal String Test: A Nonendoscopic Minimally Invasive Test That Accurately Detects Disease Activity in Eosinophilic Esophagitis.

Ackerman SJ, Kagalwalla AF, Hirano I, Gonsalves N, Katcher PM, Gupta S, Wechsler JB, Grozdanovic M, Pan Z, Masterson JC, Du J, Fantus RJ, Alumkal P, Lee JJ, Ochkur S, Ahmed F, Capocelli K, Melin-Aldana H, Biette K, Dubner A, Amsden K, Keeley K, Sulkowski M, Zalewski A, Atkins D, Furuta GT.

Am J Gastroenterol. 2019 Oct;114(10):1614-1625. doi: 10.14309/ajg.0000000000000371.

6.

Clinical relevance of esophageal subepithelial activity in eosinophilic esophagitis.

Hirano I.

J Gastroenterol. 2019 Sep 12. doi: 10.1007/s00535-019-01624-3. [Epub ahead of print] Review.

PMID:
31515617
7.

Budesonide Oral Suspension Significantly Improves Eosinophilic Esophagitis Histology Scoring System Results: Analyses From a 12-Week, Phase 2, Randomized, Placebo-controlled Trial.

Collins MH, Dellon ES, Katzka DA, Hirano I, Williams J, Lan L.

Am J Surg Pathol. 2019 Nov;43(11):1501-1509. doi: 10.1097/PAS.0000000000001361.

PMID:
31498177
8.

An immortalized cell line derived from renal erythropoietin-producing (REP) cells demonstrates their potential to transform into myofibroblasts.

Sato K, Hirano I, Sekine H, Miyauchi K, Nakai T, Kato K, Ito S, Yamamoto M, Suzuki N.

Sci Rep. 2019 Aug 2;9(1):11254. doi: 10.1038/s41598-019-47766-5.

9.

The Neural Crest as the First Production Site of the Erythroid Growth Factor Erythropoietin.

Hirano I, Suzuki N.

Front Cell Dev Biol. 2019 Jun 12;7:105. doi: 10.3389/fcell.2019.00105. eCollection 2019. Review.

10.

Effects of light conditions on growth and defense compound contents of Datura inoxia and D. stramonium.

Hirano I, Iida H, Ito Y, Park HD, Takahashi K.

J Plant Res. 2019 Jul;132(4):473-480. doi: 10.1007/s10265-019-01111-z. Epub 2019 Apr 24.

PMID:
31020486
11.

Epidemiology and implications of concurrent diagnosis of eosinophilic oesophagitis and IBD based on a prospective population-based analysis.

Limketkai BN, Shah SC, Hirano I, Bellaguarda E, Colombel JF.

Gut. 2019 Dec;68(12):2152-2160. doi: 10.1136/gutjnl-2018-318074. Epub 2019 Mar 28.

PMID:
30923072
12.

Conjunctivitis in dupilumab clinical trials.

Akinlade B, Guttman-Yassky E, de Bruin-Weller M, Simpson EL, Blauvelt A, Cork MJ, Prens E, Asbell P, Akpek E, Corren J, Bachert C, Hirano I, Weyne J, Korotzer A, Chen Z, Hultsch T, Zhu X, Davis JD, Mannent L, Hamilton JD, Teper A, Staudinger H, Rizova E, Pirozzi G, Graham NMH, Shumel B, Ardeleanu M, Wollenberg A.

Br J Dermatol. 2019 Sep;181(3):459-473. doi: 10.1111/bjd.17869. Epub 2019 May 7.

13.

GATA2 hypomorphism induces chronic myelomonocytic leukemia in mice.

Harada N, Hasegawa A, Hirano I, Yamamoto M, Shimizu R.

Cancer Sci. 2019 Apr;110(4):1183-1193. doi: 10.1111/cas.13959. Epub 2019 Feb 23.

14.

Association Between Helicobacter pylori Exposure and Decreased Odds of Eosinophilic Esophagitis-A Systematic Review and Meta-analysis.

Shah SC, Tepler A, Peek RM Jr, Colombel JF, Hirano I, Narula N.

Clin Gastroenterol Hepatol. 2019 Oct;17(11):2185-2198.e3. doi: 10.1016/j.cgh.2019.01.013. Epub 2019 Jan 16. Review.

PMID:
30659992
15.

Clinical Features at Baseline Cannot Predict Symptom Response to Placebo in Patients With Eosinophilic Esophagitis.

Hirano I, Dellon ES, Collins MH, Williams J, Lan L, Katzka DA.

Clin Gastroenterol Hepatol. 2019 Sep;17(10):2126-2128.e1. doi: 10.1016/j.cgh.2018.11.045. Epub 2018 Nov 28.

16.

Variation in Endoscopic Activity Assessment and Endoscopy Score Validation in Adults With Eosinophilic Esophagitis.

Schoepfer AM, Hirano I, Coslovsky M, Roumet MC, Zwahlen M, Kuehni CE, Hafner D, Alexander JA, Dellon ES, Gonsalves N, Leung J, Bussmann C, Collins MH, Newbury RO, Smyrk TC, Woosley JT, Yang GY, Romero Y, Katzka DA, Furuta GT, Gupta SK, Aceves SS, Chehade M, Spergel JM, Falk GW, Meltzer BA, Comer GM, Straumann A, Safroneeva E; International EEsAI Study Group.

Clin Gastroenterol Hepatol. 2019 Jul;17(8):1477-1488.e10. doi: 10.1016/j.cgh.2018.11.032. Epub 2018 Nov 23.

PMID:
30476587
17.

Consortium of Eosinophilic Gastrointestinal Disease Researchers: Advancing the Field of Eosinophilic GI Disorders Through Collaboration.

Gupta SK, Falk GW, Aceves SS, Chehade M, Collins MH, Dellon ES, Gonsalves N, Hirano I, Mukkuda VA, Peterson KA, Spergel J, Yang GY, Furuta GT, Rothenberg ME; Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR).

Gastroenterology. 2019 Mar;156(4):838-842. doi: 10.1053/j.gastro.2018.10.057. Epub 2018 Nov 17. No abstract available.

PMID:
30452923
18.

RPC4046, a Monoclonal Antibody Against IL13, Reduces Histologic and Endoscopic Activity in Patients With Eosinophilic Esophagitis.

Hirano I, Collins MH, Assouline-Dayan Y, Evans L, Gupta S, Schoepfer AM, Straumann A, Safroneeva E, Grimm M, Smith H, Tompkins CA, Woo A, Peach R, Frohna P, Gujrathi S, Penenberg DN, Li C, Opiteck GJ, Olson A, Aranda R, Rothenberg ME, Dellon ES; HEROES Study Group.

Gastroenterology. 2019 Feb;156(3):592-603.e10. doi: 10.1053/j.gastro.2018.10.051. Epub 2018 Nov 2.

19.

Oral delivery of fluticasone powder improves esophageal eosinophilic inflammation and symptoms in adults with eosinophilic esophagitis.

Kia L, Nelson M, Zalewski A, Gregory D, Gonsalves N, Straumann A, Hirano I.

Dis Esophagus. 2018 Dec 1;31(12). doi: 10.1093/dote/doy098.

PMID:
30380044
20.

Authors' response.

Spergel JM, Dellon ES, Liacouras CA, Hirano I, Molina-Infante J, Bredenoord AJ, Furuta GT.

Ann Allergy Asthma Immunol. 2018 Dec;121(6):747-748. doi: 10.1016/j.anai.2018.10.015. Epub 2018 Oct 13. No abstract available.

PMID:
30326321
21.

How to Approach a Patient With Eosinophilic Esophagitis.

Hirano I.

Gastroenterology. 2018 Sep;155(3):601-606. doi: 10.1053/j.gastro.2018.08.001. Epub 2018 Aug 3. No abstract available.

PMID:
30080994
22.

Summary of the updated international consensus diagnostic criteria for eosinophilic esophagitis: AGREE conference.

Spergel JM, Dellon ES, Liacouras CA, Hirano I, Molina-Infante J, Bredenoord AJ, Furuta GT; participants of AGREE.

Ann Allergy Asthma Immunol. 2018 Sep;121(3):281-284. doi: 10.1016/j.anai.2018.05.035. Epub 2018 Jul 18. No abstract available.

23.

Updated International Consensus Diagnostic Criteria for Eosinophilic Esophagitis: Proceedings of the AGREE Conference.

Dellon ES, Liacouras CA, Molina-Infante J, Furuta GT, Spergel JM, Zevit N, Spechler SJ, Attwood SE, Straumann A, Aceves SS, Alexander JA, Atkins D, Arva NC, Blanchard C, Bonis PA, Book WM, Capocelli KE, Chehade M, Cheng E, Collins MH, Davis CM, Dias JA, Di Lorenzo C, Dohil R, Dupont C, Falk GW, Ferreira CT, Fox A, Gonsalves NP, Gupta SK, Katzka DA, Kinoshita Y, Menard-Katcher C, Kodroff E, Metz DC, Miehlke S, Muir AB, Mukkada VA, Murch S, Nurko S, Ohtsuka Y, Orel R, Papadopoulou A, Peterson KA, Philpott H, Putnam PE, Richter JE, Rosen R, Rothenberg ME, Schoepfer A, Scott MM, Shah N, Sheikh J, Souza RF, Strobel MJ, Talley NJ, Vaezi MF, Vandenplas Y, Vieira MC, Walker MM, Wechsler JB, Wershil BK, Wen T, Yang GY, Hirano I, Bredenoord AJ.

Gastroenterology. 2018 Oct;155(4):1022-1033.e10. doi: 10.1053/j.gastro.2018.07.009. Epub 2018 Sep 6. Review.

24.

Heterogeneity in Clinical, Endoscopic, and Histologic Outcome Measures and Placebo Response Rates in Clinical Trials of Eosinophilic Esophagitis: A Systematic Review.

Ma C, van Rhijn BD, Jairath V, Nguyen TM, Parker CE, Aceves SS, Furuta GT, Gupta SK, Katzka DA, Safroneeva E, Schoepfer AM, Straumann A, Spergel JM, Pai RK, Feagan BG, Hirano I, Dellon ES, Bredenoord AJ.

Clin Gastroenterol Hepatol. 2018 Nov;16(11):1714-1729.e3. doi: 10.1016/j.cgh.2018.06.005. Epub 2018 Jun 14.

25.

Safety and Efficacy of Budesonide Oral Suspension Maintenance Therapy in Patients With Eosinophilic Esophagitis.

Dellon ES, Katzka DA, Collins MH, Gupta SK, Lan L, Williams J, Hirano I.

Clin Gastroenterol Hepatol. 2019 Mar;17(4):666-673.e8. doi: 10.1016/j.cgh.2018.05.051. Epub 2018 Jun 12.

26.

Biological therapies for eosinophilic gastrointestinal diseases.

Wechsler JB, Hirano I.

J Allergy Clin Immunol. 2018 Jul;142(1):24-31.e2. doi: 10.1016/j.jaci.2018.05.018. Epub 2018 May 31. Review.

27.

Alignment of parent- and child-reported outcomes and histology in eosinophilic esophagitis across multiple CEGIR sites.

Aceves SS, King E, Collins MH, Yang GY, Capocelli KE, Abonia JP, Atkins D, Bonis PA, Carpenter CL, Dellon ES, Eby MD, Falk GW, Gonsalves N, Gupta SK, Hirano I, Kocher K, Krischer JP, Leung J, Lipscomb J, Menard-Katcher P, Mukkada VA, Pan Z, Spergel JM, Sun Q, Wershil BK, Rothenberg ME, Furuta GT; Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR).

J Allergy Clin Immunol. 2018 Jul;142(1):130-138.e1. doi: 10.1016/j.jaci.2018.05.014. Epub 2018 May 29.

28.

New developments in patients with eosinophilic gastrointestinal diseases presented at the CEGIR/TIGERS Symposium at the 2018 American Academy of Allergy, Asthma & Immunology Meeting.

Spergel JM, Aceves SS, Kliewer K, Gonsalves N, Chehade M, Wechsler JB, Groetch M, Friedlander J, Dellon ES, Book W, Hirano I, Muir AB, Cianferoni A, Spencer L, Liacouras CA, Cheng E, Kottyan L, Wen T, Platts-Mills T, Rothenberg ME.

J Allergy Clin Immunol. 2018 Jul;142(1):48-53. doi: 10.1016/j.jaci.2018.05.005. Epub 2018 May 24.

29.

Eosinophilic oesophagitis endotype classification by molecular, clinical, and histopathological analyses: a cross-sectional study.

Shoda T, Wen T, Aceves SS, Abonia JP, Atkins D, Bonis PA, Caldwell JM, Capocelli KE, Carpenter CL, Collins MH, Dellon ES, Eby MD, Gonsalves N, Gupta SK, Falk GW, Hirano I, Menard-Katcher P, Kuhl JT, Krischer JP, Leung J, Mukkada VA, Spergel JM, Trimarchi MP, Yang GY, Zimmermann N, Furuta GT, Rothenberg ME; Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR).

Lancet Gastroenterol Hepatol. 2018 Jul;3(7):477-488. doi: 10.1016/S2468-1253(18)30096-7. Epub 2018 May 3.

30.

Assessing Adherence and Barriers to Long-Term Elimination Diet Therapy in Adults with Eosinophilic Esophagitis.

Wang R, Hirano I, Doerfler B, Zalewski A, Gonsalves N, Taft T.

Dig Dis Sci. 2018 Jul;63(7):1756-1762. doi: 10.1007/s10620-018-5045-0. Epub 2018 Apr 2.

31.

Contributions From Gastroenterology: Acid Peptic Disorders, Barrett's Esophagus and Eosinophilic Esophagitis.

Souza RF, Rubenstein JH, Kao JY, Hirano I.

Gastroenterology. 2018 Apr;154(5):1209-1214. doi: 10.1053/j.gastro.2017.12.023. Epub 2018 Mar 8. No abstract available.

PMID:
29524399
32.

Stereoselective effects of lactate enantiomers on the enhancement of 3T3-L1 adipocyte differentiation.

Harada N, Hirano I, Inui H, Yamaji R.

Biochem Biophys Res Commun. 2018 Mar 25;498(1):105-110. doi: 10.1016/j.bbrc.2018.02.198. Epub 2018 Mar 5.

PMID:
29501496
33.

Impact on Health-Related Quality of Life in Adults with Eosinophilic Gastritis and Gastroenteritis: A Qualitative Assessment.

Bedell A, Taft T, Craven MR, Guadagnoli L, Hirano I, Gonsalves N.

Dig Dis Sci. 2018 May;63(5):1148-1157. doi: 10.1007/s10620-018-4978-7. Epub 2018 Feb 23.

34.

New Developments in the Diagnosis, Therapy, and Monitoring of Eosinophilic Esophagitis.

Patel RV, Hirano I.

Curr Treat Options Gastroenterol. 2018 Mar;16(1):15-26. doi: 10.1007/s11938-018-0167-1. Review.

35.

Creating a multi-center rare disease consortium - the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR).

Cheng K, Gupta SK, Kantor S, Kuhl JT, Aceves SS, Bonis PA, Capocelli KE, Carpenter C, Chehade M, Collins MH, Dellon ES, Falk GW, Gopal-Srivastava R, Gonsalves N, Hirano I, King EC, Leung J, Krischer JP, Mukkada VA, Schoepfer A, Spergel JM, Straumann A, Yang GY, Furuta GT, Rothenberg ME.

Transl Sci Rare Dis. 2017 Dec 18;2(3-4):141-155. doi: 10.3233/TRD-170016.

36.

Eosinophilic Esophagitis Reference Score Accurately Identifies Disease Activity and Treatment Effects in Children.

Wechsler JB, Bolton SM, Amsden K, Wershil BK, Hirano I, Kagalwalla AF.

Clin Gastroenterol Hepatol. 2018 Jul;16(7):1056-1063. doi: 10.1016/j.cgh.2017.12.019. Epub 2017 Dec 15.

37.

Editorial: long-term effectiveness of elimination diet therapy for eosinophilic oesophagitis-is the glass half full or half empty?

Gonsalves N, Hirano I.

Aliment Pharmacol Ther. 2018 Jan;47(1):135-136. doi: 10.1111/apt.14379. No abstract available.

38.

Future Directions in Eosinophilic Esophagitis.

Hirano I.

Gastrointest Endosc Clin N Am. 2018 Jan;28(1):111-122. doi: 10.1016/j.giec.2017.07.010. Epub 2017 Oct 12. Review.

PMID:
29129295
39.

Prospective assessment of disease-specific quality of life in adults with eosinophilic esophagitis.

Stern E, Taft T, Zalewski A, Gonsalves N, Hirano I.

Dis Esophagus. 2018 Apr 1;31(4). doi: 10.1093/dote/dox128.

PMID:
29088336
40.

Induction of erythropoietin gene expression in epithelial cells by chemicals identified in GATA inhibitor screenings.

Kaneko H, Katoh T, Hirano I, Hasegawa A, Tsujita T, Yamamoto M, Shimizu R.

Genes Cells. 2017 Nov;22(11):939-952. doi: 10.1111/gtc.12537. Epub 2017 Oct 18.

41.

Comparison of endoscopy and radiographic imaging for detection of esophageal inflammation and remodeling in adults with eosinophilic esophagitis.

Nelson MJ, Miller FH, Moy N, Zalewski A, Gonsalves N, Gregory DL, Hirano I.

Gastrointest Endosc. 2018 Apr;87(4):962-968. doi: 10.1016/j.gie.2017.09.037. Epub 2017 Oct 6.

PMID:
28989006
42.

Improvement in Esophageal Distensibility in Response to Medical and Diet Therapy in Eosinophilic Esophagitis.

Carlson DA, Hirano I, Zalewski A, Gonsalves N, Lin Z, Pandolfino JE.

Clin Transl Gastroenterol. 2017 Oct 5;8(10):e119. doi: 10.1038/ctg.2017.47.

43.

Editorial: oesophageal dilation in eosinophilic oesophagitis-can and should, but when and how?

Kia L, Hirano I.

Aliment Pharmacol Ther. 2017 Sep;46(5):556-557. doi: 10.1111/apt.14216. No abstract available.

44.

Epidemiology and Natural History of Eosinophilic Esophagitis.

Dellon ES, Hirano I.

Gastroenterology. 2018 Jan;154(2):319-332.e3. doi: 10.1053/j.gastro.2017.06.067. Epub 2017 Aug 1. Review.

45.

An Overview of Dietary Therapies for the Treatment of Eosinophilic Esophagitis.

Hirano I.

Gastroenterol Hepatol (N Y). 2017 Jun;13(6):381-383. No abstract available.

46.

Reply.

Pandolfino J, Hirano I, Boeckxstaens G.

Clin Gastroenterol Hepatol. 2017 Aug;15(8):1314-1315. doi: 10.1016/j.cgh.2017.04.037. Epub 2017 May 4. No abstract available.

PMID:
28479499
47.

White Paper AGA: Drug Development for Eosinophilic Esophagitis.

Hirano I, Spechler S, Furuta G, Dellon ES.

Clin Gastroenterol Hepatol. 2017 Aug;15(8):1173-1183. doi: 10.1016/j.cgh.2017.03.016. Epub 2017 Mar 22. Review.

48.

Application of the Functional Lumen Imaging Probe to Esophageal Disorders.

Carlson DA, Hirano I.

Curr Treat Options Gastroenterol. 2017 Mar;15(1):10-25. doi: 10.1007/s11938-017-0116-4. Review.

PMID:
28265971
49.

Functional Lumen Imaging Probe for the Management of Esophageal Disorders: Expert Review From the Clinical Practice Updates Committee of the AGA Institute.

Hirano I, Pandolfino JE, Boeckxstaens GE.

Clin Gastroenterol Hepatol. 2017 Mar;15(3):325-334. doi: 10.1016/j.cgh.2016.10.022. Review.

50.

Renal Anemia Model Mouse Established by Transgenic Rescue with an Erythropoietin Gene Lacking Kidney-Specific Regulatory Elements.

Hirano I, Suzuki N, Yamazaki S, Sekine H, Minegishi N, Shimizu R, Yamamoto M.

Mol Cell Biol. 2017 Feb 1;37(4). pii: e00451-16. doi: 10.1128/MCB.00451-16. Print 2017 Feb 15.

Supplemental Content

Loading ...
Support Center